CRISPR Therapeutics News

CRISPR Therapeutics Analyst Ratings

BenzingaApr 18 12:10 ET

CRISPR Therapeutics Analyst Ratings

BenzingaApr 11 06:37 ET

Crispr Therapeutics AG: A Buy Rating Backed by Innovative Gene-Editing Prospects and Strategic Growth

TipRanksApr 11 06:05 ET

Buy Rating Affirmed for Crispr Therapeutics AG on Promising Gene Editing Developments and Expanding Treatment Pipeline

TipRanksApr 3 01:46 ET

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)

TipRanksMar 29 04:30 ET

CRISPR Therapeutics Analyst Ratings

BenzingaMar 6 08:09 ET

Crispr Therapeutics AG (CRSP) Receives a Buy From Truist Financial

TipRanksFeb 27 07:47 ET

CRISPR Therapeutics Analyst Ratings

BenzingaFeb 26 10:45 ET

CRISPR Therapeutics Analyst Ratings

BenzingaFeb 22 10:41 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH), Crispr Therapeutics AG (CRSP) and Ansell (OtherANSLF)

TipRanksFeb 22 07:24 ET

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)

TipRanksFeb 22 07:11 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Icon (ICLR) and Crispr Therapeutics AG (CRSP)

TipRanksFeb 22 05:12 ET

Buy Rating for Crispr Therapeutics AG: Strong Financials and Promising Gene-Editing Pipeline

TipRanksFeb 21 18:35 ET

CRISPR Therapeutics Analyst Ratings

BenzingaFeb 21 11:39 ET

Buy Rating Affirmed for Crispr Therapeutics AG on Robust Pipeline and Expanding Global Reach

TipRanksFeb 21 11:25 ET

Analysts Conflicted on These Healthcare Names: Globus Medical (GMED) and Crispr Therapeutics AG (CRSP)

TipRanksFeb 21 10:30 ET

CRISPR Therapeutics Analyst Ratings

BenzingaFeb 15 06:56 ET

Crispr Therapeutics AG: Buy Rating Affirmed Amid Clinical Milestones and Strong Financial Position

TipRanksFeb 15 01:36 ET

Piper Sandler Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

TipRanksFeb 14 07:46 ET

Buy Rating Affirmed for Crispr Therapeutics With Increased Price Target Following EU Approval and Capital Boost

TipRanksFeb 13 12:35 ET